

PROCEDURE

Initial Authorization Criteria:

Must meet all of the criteria listed under the respective diagnosis:

For All Diagnoses:

- Must be at least 18 years of age. However, members under the age of 18 with a confirmed diagnosis of short bowel syndrome are considered on a case-by-case basis in consultation with the Medical Director.
- Must have chart documentation indicating a diagnosis of short bowel syndrome, defined as all of the following:
 - Must have documented malabsorption from the small intestine that is marked by diarrhea, malnutrition, and steatorrhea and that results from resection of the small intestine
 - Must have a small intestine <200 cm in length
 - Must have one of the following:
 - Must have an intact stomach and duodenum as well as ≥30% of functioning colon with at least 15 cm of intact jejunum and/or ileum
 - Must have an intact stomach and duodenum as well as <30% functioning colon with at least 90 cm intact jejunum and/or ileum.
- Must also be receiving adequate nutritional support as determined by the Provider
- Must not have active malignancy

Reauthorization Criteria:

All prior authorization renewals are reviewed on an annual basis to determine the Medical Necessity for continuation of therapy. Authorization may be extended at one-year intervals based upon chart documentation from the prescriber that the member's disease has improved based upon the prescriber's assessment while on therapy.

Limitations:

Length of Authorization (if above criteria met)	
Initial Authorization	Up to 4 weeks
Reauthorization	Up to 1 year

If the established criteria are not met, the request is referred to a Medical Director for review.

REFERENCES

1. Byrne TA, Morrissey TB, Nattakom TV, et al. Growth hormone, glutamine, and a modified diet enhance nutrient absorption in patients with short-bowel syndrome. *J Parenter Enteral Nutr.* 1995;19:296-302.
2. Byrne TA, Persinger RL, Young LS, et al. A new treatment for patients with short-bowel syndrome. Growth hormone, glutamine, and a modified diet. *Ann Surg.* 1995;222:243-255.
3. Sequy D, Vahedi K, Kapel N, et al. Low-dose growth hormone in adult home parenteral nutrition-dependent short bowel syndrome patients: a positive study. *Gastroenterol.* 2003;124:293-302.
4. Zorbtive [Product Information]. Serono, Inc. Rockland, MA. January 2004



Zorbtive (somatropin)
POLICY NUMBER: RX.PA.042.E
REVISION DATE: 4/13
PAGE NUMBER: 3 of 3

RECORD RETENTION

Records Retention for Evolent Health documents, regardless of medium, are provided within the Evolent Health records retention policy and as indicated in CORP.028.E Records Retention Policy and Procedure.

REVIEW HISTORY

DESCRIPTION OF REVIEW / REVISION	DATE APPROVED
<i>Annual Review</i>	<i>02/17, 02/18</i>

